Imperial College London
Portrait Picture

Dr Gaia Kiru

Faculty of Medicine, School of Public Health

Head of Operations and Partnerships
 
 
 
//

Contact

 

g.kiru

 
 
//

Location

 

Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ray:2021:eurjpc/zwaa047,
author = {Ray, K and Molemans, B and Schoonen, WM and Giovas, P and Bray, S and Kiru, G and Murphy, J and Banach, M and De, Servi S and Gaita, D and Gouni-Berthold, I and Hovingh, GK and Jozwaik, JJ and Jukema, JW and Gabor, Kiss R and Kownator, S and Iversen, HK and Maher, V and Masana, L and Parkhomenko, A and Peeters, A and Clifford, P and Raslova, K and Siostrzonek, P and Romeo, S and Tousoulis, D and Vlachopoulos, C and Vrablik, M and Catapano, AL and Poulter, NR and DA, VINCI study},
doi = {eurjpc/zwaa047},
journal = {European Journal of Preventive Cardiology},
pages = {1279--1289},
title = {EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study},
url = {http://dx.doi.org/10.1093/eurjpc/zwaa047},
volume = {28},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AimsTo provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement.Methods and resultsAn 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52–56] achieved their risk-based 2016 goal and 33% (95% CI 32–35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate–high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination).ConclusionGaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.
AU  - Ray,K
AU  - Molemans,B
AU  - Schoonen,WM
AU  - Giovas,P
AU  - Bray,S
AU  - Kiru,G
AU  - Murphy,J
AU  - Banach,M
AU  - De,Servi S
AU  - Gaita,D
AU  - Gouni-Berthold,I
AU  - Hovingh,GK
AU  - Jozwaik,JJ
AU  - Jukema,JW
AU  - Gabor,Kiss R
AU  - Kownator,S
AU  - Iversen,HK
AU  - Maher,V
AU  - Masana,L
AU  - Parkhomenko,A
AU  - Peeters,A
AU  - Clifford,P
AU  - Raslova,K
AU  - Siostrzonek,P
AU  - Romeo,S
AU  - Tousoulis,D
AU  - Vlachopoulos,C
AU  - Vrablik,M
AU  - Catapano,AL
AU  - Poulter,NR
AU  - DA,VINCI study
DO  - eurjpc/zwaa047
EP  - 1289
PY  - 2021///
SN  - 2047-4873
SP  - 1279
TI  - EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study
T2  - European Journal of Preventive Cardiology
UR  - http://dx.doi.org/10.1093/eurjpc/zwaa047
UR  - https://academic.oup.com/eurjpc/article/28/11/1279/5898664
UR  - http://hdl.handle.net/10044/1/83094
VL  - 28
ER  -
Download